Skip to main content
OpenTrials
Completed

NCT Number: NCT05449041

Bulbicam Validation on Glaucoma- and Cataract Patients

The aim is to investigate repeatability and stability of the six OTH-related Bulbicam tests in patients suffering from Glaucoma (GLA), b) Cataract (CAT) and matched healthy controls (HC).

The study population consists of the three subpopulations: 1) Patients suffering from GLA; 2) Patients suffering from CAT and 3) Gender- and age-matched HC without any eye diseases.

Bulbicam will be used in the study including six tests and the standard method will be used initially for measurements of "Visual Field" and "Pupil"

The study will be performed as a controlled, open, and non-randomized, stratified observational single center study. The stratification factors will be pathology and the degree of disease. Within each of the four strata, healthy matched controls related to gender and age (1:1) will be included.

The main variables will be the variables recorded at the six Bulbicam and the supporting variables will be recorded by the Standard (ST) investigation. The central variables related to Glaucoma will be the GAT and iCare pressure, "Seen /unseen "," Time until the given point is recorded as seen", "the light in decibel when the point is seen", X- and Y-coordinates and "Pupil diameter in mm".

The central variables related to cataract will be "Pupil diameter", "OCT RNFL ", "Seen /unseen "," Time until the given point is recorded as seen", "the light in decibel when the point is seen" and the X- and Y-coordinates.

Participants, who fulfil the inclusion criteria; do not meet any of the exclusion criteria and willing to give informed consent to participate will receive an appointment for starting the study. The Bulbicam examination will be performed twice a day with a rest period of one hour between each registration. This procedure will be repeated the following two days. All demographic data, social factors and history of disease will be recorded at screening.

Sixteen GLA-patients and 16 CAT-patients equally divided into two substrata will be recruited from the two participating hospitals. For each included patient, one gender- and age-matched HC will be recruited. In total 16 GLA-patients with 16 HC and 16 CAT-patients with 16 HC will be included in the study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glaucoma Eye Cataract Eye Diseases Lens Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Meddoc

Skjetten, Akershus, 2013, Norway

About this study

Aim

  • To investigate repeatability and stability of the six OTH-related Bulbicam tests in patients suffering from a) Glaucoma (GLA), b) Cataract (CAT) and matched healthy controls (HC).
  • To compare Bulbicam and the standard method on measurements of Visual field and Pupil
  • To contribute to establishment of normal range for GLA and CAT patients with different degrees in the disease development related to the Bulbicam tests.
  • To contribute to establishment of normal range for a normal population without eye-disease related to the Bulbicam tests. Study population consists of the following three study populations: 1) Patients suffering from GLA of both genders above 18 years of age with different disease degree; 2) Patients suffering from CAT of both genders above 18 years of age with different disease degree; 3) Gender- and age-matched HC without any eye diseases.

Trial equipment: Bulbicam will be used in the study and the following six tests will be performed at each investigation: "Visual Field", "Ptosis", Dynamic Acuity", "Dynamic Contrast ", "Dark Adaption" and "Pupil". The standard method will be used initially for measurements of "Visual Field" and "Pupil"

Design:

The study will be performed as a controlled, open, and non-randomized, stratified observational single center study. The stratification factors will be pathology (GLA&CAT) and the degree of disease. Within each of the four strata, healthy matched controls related to gender and age (1:1) will be included. The degree of GLA is defined as follows:

  • Mild glaucoma
  • Moderate glaucoma
  • Severe glaucoma

The degree of CAT is defined as follows:

  • Cataract Nuclear Sclerosis - Grade 1
  • Cataract Nuclear Sclerosis - Grade 2

Higher grade cataracts are difficult to have occurred in Norway and thus excluded from this study.

For each included patient, a gender- and age-matched HV will be included. All included participants will perform Bulbicam eye-investigation twice at three flowing days with a rest period of at least one hour. Each investigation includes same six Bulbicam tests. The Standard method will only be performed once as the first investigation at day 1 for measurements of "Visual Field" and "Pupil".

Main variables will be the variables recorded at the six Bulbicam tests. Supporting Variables will be recorded by the Standard (ST) investigation for Glaucoma and Cataract.

The central variables related to Glaucoma will be the GAT and iCare pressure, "Seen /unseen "," Time until the given point is recorded as seen", "the light in decibel when the point is seen", X- and Y-coordinates and "Pupil diameter in mm". The central variables related to cataract will be "Pupil diameter", "OCT RNFL ", "Seen /unseen "," Time until the given point is recorded as seen", "the light in decibel when the point is seen" and the X- and Y-coordinates.

Study procedure:

Participants, who fulfil the inclusion criteria; do not meet any of the exclusion criteria and willing to give informed consent to participate will receive an appointment for starting the study. The Bulbicam examination will be performed twice a day with a rest period of one hour between each registration. This procedure will be repeated the following two days. All demographic data, social factors and history of disease will be recorded at screening. Additionally, the quality of life (QoL) questionnaires EQ-5D-5L developed by EuroQol will be recorded initially as individual baseline values. The Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be used for measuring and classifying the tolerability and toxicity at the end of each day of investigation.

Sample size:

Sixteen GLA-patients and 16 CAT-patients equally divided into two substrata will be recruited from the two participating hospitals. For each included patient, one gender- and age-matched HC will be recruited. In total 16 GLA-patients with 16 HC and 16 CAT-patients with 16 HC will be included in the study. All together the study will include 64 participants.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with either Glaucoma or Cataract of both gender
  • Passed the age of 18 years
  • Without any other eye disease

Exclusion criteria

  • Other visual disturbances and blindness
  • Posterior Chamber Intraocular Lens (PCIOL)
  • Physical or psychiatric disease, which may disturb the measuring procedure
  • Patients who are not able to perform eye movements, so no full paresis of any ocular muscles
  • Patients whose visual acuity is less than 0.1 in any eye, as these will not be able to focus on the test stimuli.
  • Patients whose visible part of the eye is abnormal, such as subconjunctival hemorrhages or deformed pupils
  • Patients whose pupils are not able to respond normally to dilation or contraction due to damaged nerves, mechanical damage of the pupil etc.
  • With known alcoholic and drug dependency
  • Not able to understand information.
  • Not willing to give written consent to participate in the study.

Treatment and study plan

Bulbicam

Device

Measurement of eye pressure; Accuracy diagram; Contrast chart; Visual field, Pupil size

Other names: Standard eye examination devices

Primary outcomes

  1. GAT

    Time frame: 0 hour

    Measurement of eye-pressure in mmHg

  2. GAT

    Time frame: 1 hour

    Measurement of eye-pressure in mmHg

  3. GAT

    Time frame: 24 hours

    Measurement of eye-pressure in mmHg

  4. GAT

    Time frame: 25 hours

    Measurement of eye-pressure in mmHg

  5. GAT

    Time frame: 36 hours

    Measurement of eye-pressure in mmHg

  6. GAT

    Time frame: 37 hours

    Measurement of eye-pressure in mmHg

  7. Visual Field

    Time frame: 0 hour

    Saccadic Reaction Time in ms

  8. Visual Field

    Time frame: 1 hour

    Saccadic Reaction Time in ms

  9. Visual Field

    Time frame: 24 hours

    Saccadic Reaction Time in ms

  10. Visual Field

    Time frame: 25 hours

    Saccadic Reaction Time in ms

  11. Visual Field

    Time frame: 36 hours

    Saccadic Reaction Time in ms

  12. Visual Field

    Time frame: 37 hours

    Saccadic Reaction Time in ms

  13. Ptosis

    Time frame: 0 hour

    MDR in mm

  14. Ptosis

    Time frame: 1 hour

    MDR in mm

  15. Ptosis

    Time frame: 24 hours

    MDR in mm

  16. Ptosis

    Time frame: 25 hours

    MDR in mm

  17. Ptosis

    Time frame: 36 hours

    MDR in mm

  18. Ptosis

    Time frame: 37 hours

    MDR in mm

  19. Dynamic Acuity

    Time frame: 0 hour

    Vision acuity in LogMar

  20. Dynamic Acuity

    Time frame: 1 hour

    Vision acuity in LogMar

  21. Dynamic Acuity

    Time frame: 24 hours

    Vision acuity in LogMar

  22. Dynamic Acuity

    Time frame: 25 hours

    Vision acuity in LogMar

  23. Dynamic Acuity

    Time frame: 36 hours

    Vision acuity in LogMar

  24. Dynamic Acuity

    Time frame: 37 hours

    Vision acuity in LogMar

  25. Dynamic Contrast

    Time frame: 0 hour

    Contrast sensitivity in LogCon

  26. Dynamic Contrast

    Time frame: 1 hour

    Contrast sensitivity in LogCon

  27. Dynamic Contrast

    Time frame: 24 hours

    Contrast sensitivity in LogCon

  28. Dynamic Contrast

    Time frame: 25 hours

    Contrast sensitivity in LogCon

  29. Dynamic Contrast

    Time frame: 36 hours

    Contrast sensitivity in LogCon

  30. Dynamic Contrast

    Time frame: 37 hours

    Contrast sensitivity in LogCon

  31. Dark Adaptation

    Time frame: 0 hour

    Fixed contrast; variable frequency in Hz

  32. Dark Adaptation

    Time frame: 1 hour

    Fixed contrast; variable frequency in Hz

  33. Dark Adaptation

    Time frame: 24 hours

    Fixed contrast; variable frequency in Hz

  34. Dark Adaptation

    Time frame: 25 hours

    Fixed contrast; variable frequency in Hz

  35. Dark Adaptation

    Time frame: 36 hours

    Fixed contrast; variable frequency in Hz

  36. Dark Adaptation

    Time frame: 37 hours

    Fixed contrast; variable frequency in Hz

  37. Pupil

    Time frame: 0 hour

    Diameter (mm)

  38. Pupil

    Time frame: 1 hour

    Diameter (mm)

  39. Pupil

    Time frame: 24 hours

    Diameter (mm)

  40. Pupil

    Time frame: 25 hours

    Diameter (mm)

  41. Pupil

    Time frame: 36 hours

    Diameter (mm)

  42. Pupil

    Time frame: 37 hours

    Diameter (mm)

Sponsors and collaborators

Lead sponsor

Meddoc

Other

Registry information

Official study title

Validation of Bulbicam for Use on Patient Suffering From Glaucoma (GLA) and Cataract (CAT)

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Jul 8, 2022
Registry last updated
May 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.